21036 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof; Enzymes; Proenzymes; Derivatives thereof; Hydrolases (3) acting on peptide bonds (3.4); Serine endopeptidases (3.4.21) Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
FACTOR IX VARIANT POLYPEPTIDES FOR ADMINISTRATION TO SOFT TISSUE
#2COMPOSITIONS AND METHODS FOR IN VIVO NUCLEASE-MEDIATED GENE TARGETING FOR THE TREATMENT OF GENETIC DISORDERS IN ADULT PATIENTS
#3COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE
#4TARGETED INTEGRATION AT ALPHA-GLOBIN LOCUS IN HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS
#5MODIFIED FACTOR XA POLYPEPTIDES AND METHODS OF USE
#6METHODS AND COMPOSITIONS FOR RE-DOSING AAV USING ANTI-CD40 ANTAGONISTIC ANTIBODY TO SUPPRESS HOST ANTI-AAV ANTIBODY RESPONSE
#7METHODS OF INDUCING IMMUNE TOLERANCE TO CLOTTING FACTORS
#8COMPOSITIONS AND METHODS FOR EXPRESSING FACTOR IX
#9METHODS AND COMPOSITIONS FOR USING PLASMA CELL DEPLETING AGENTS AND/OR B CELL DEPLETING AGENTS TO SUPPRESS HOST ANTI-AAV ANTIBODY RESPONSE AND ENABLE AAV TRANSDUCTION AND RE-DOSING
#10FX ACTIVATION PROCESS AND ITS USE IN THE PREPARATION OF A FXA COMPOSITION
#11CLOTTING FACTOR PREPARATIONS FOR DELIVERY INTO TISSUE OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
#12UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
#13FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION
#14LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE
#15Lipid Nanoparticle Compositions and Methods for mRNA Delivery
#16TISSUE FACTOR PATHWAY INHIBITOR ANTIBODIES AND USES THEREOF
#17STABILIZED FACTOR IX FORMULATIONS CONTAINING TREHALOSE
#18LYOPHILIZED FACTOR IX FORMULATIONS
#19HEMOSTATIC COMPOSITION CONTAINING RECOMBINANT HUMAN CLOTTING FACTORS, AND METHOD OF PRODUCING
#20METHODS OF TREATING HEMOPHILIC ARTHROPATHY USING CHIMERIC CLOTTING FACTORS
#21Lipid Nanoparticle Compositions and Methods for mRNA Delivery
#22DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS
#23DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS
#24MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
#25SYSTEMS FOR EXTRACTING PROTEINS FROM A BLOOD-BASED MATERIAL
#26DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS
#27DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS
#28NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS
#29MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE
#30MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS
#31PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING
#32SYSTEMS AND METHODS FOR NUCLEIC ACID EXPRESSION IN VIVO
#33MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
#34Lipid Formulations for Delivery of Messenger RNA
#35STABLE EXPRESSION OF AAV VECTORS IN JUVENILE SUBJECTS
#36DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS
#37COMBINATION THERAPY WITH COAGULATION FACTORS AND MULTISPECIFIC ANTIBODIES
#38CLOTTING FACTOR PREPARATIONS FOR DELIVERY INTO TISSUE OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
#39POPULATION PHARMACOKINETICS TOOLS AND USES THEREOF
#40COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS
#41UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
#42MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
#43MODIFIED FACTOR IX, AND COMPOSITIONS, METHODS AND USES FOR GENE TRANSFER TO CELLS, ORGANS, AND TISSUES
#44Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
#45METHODS AND COMPOSITIONS RELATED TO A TISSUE FACTOR-TARGETING IGG3 IMMUNOCONJUGATES
#46ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
#47CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS
#48Macrophage Stimulating 1 Receptor (MST1R) Variants And Uses Thereof
#49HAEMORRHAGE INHIBITING COMPOSITIONS AND METHODS INVOLVING THE SAME
#50SHORT-ACTING HEPARIN-BASED ANTICOAGULANT COMPOUNDS AND METHODS
#51COAGULATION FACTOR IX WITH IMPROVED PHARMACOKINETICS
#52Tissue factor pathway inhibitor antibodies and uses thereof
#53A SYSTEM TO IMPROVE HAEMOSTATIC CONTROL
#54HIGH-ACTIVITY BLOOD COAGULATION FACTOR XI MUTANT ALA570THR
#55Lipid nanoparticle compositions and methods for mRNA delivery
#56METHODS AND COMPOSITIONS FOR TRANSDUCING HEMATOPOIETIC STEM AND PROGENITOR CELLS IN VIVO
#57FACTOR IX POLYPEPTIDE FORMULATIONS
#58SHORT-ACTING FACTOR VII POLYPEPTIDES
#59Liver-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof
#60LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY
#61Lipid nanoparticle compositions and methods for MRNA delivery
#62Lipid nanoparticle compositions and methods for MRNA delivery
#63CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS
#64Methods And Devices For Detection Of Anticoagulants In Plasma And Whole Blood
#65Methods And Devices For Detection Of Anticoagulants In Plasma And Whole Blood
#66Methods And Devices For Detection Of Anticoagulants In Plasma And Whole Blood
#67Modified factor IX, and compositions, methods and uses for gene transfer to cells, organs, and tissues
#68Chromatographic methods for purification of proteins from plasma
#69ENGINEERED TARGET SPECIFIC NUCLEASES
#70Translatable molecules and synthesis thereof
#71METHODS OF TREATING NEUROLOGICAL DISORDERS
#72Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#73Vectors for Liver-Directed Gene Therapy of Hemophilia and Methods and Use Thereof
#74UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
#75THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES
#76Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
#77BLOOD FACTOR MONITORING ASSAY AND USES THEREOF
#78Methods for Extracting Proteins from a Blood-Based Material
#79Lipid nanoparticle compositions and methods for mRNA delivery
#80LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY
#81Lyophilized formulations for factor XA antidote
#82Lipid formulations for delivery of messenger RNA
#83FACTOR IX GENE THERAPY
#84ISOLATED MODIFIED VP1 CAPSID PROTEIN OF AAV5
#85Prohemostatic proteins for the treatment of bleeding
#86PROCOAGULANT COMPOUNDS
#87TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS
#88Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
#89B CELLS FOR IN VIVO DELIVERY OF THERAPEUTIC AGENTS AND DOSAGES THEREOF
#90Long-acting coagulation factors and methods of producing same
#91FACTOR IX VARIANTS AND USES THEREOF IN THERAPY
#92COMBINATION OF FACTOR VII AND AN ANTI-FACTOR IX/X BISPECIFIC ANTIBODY
#93CHIMERIC CLOTTING FACTORS
#94METHODS FOR TREATING INTRACRANIAL HEMORRHAGE AND ASSESSING EFFICACY
#95COMBINATION THERAPY WITH COAGULATION FACTORS AND MULTISPECIFIC ANTIBODIES
#96METHODS AND COMPOSITIONS RELATED TO IMPROVED FACTOR VIII LONG HALF-LIFE COAGULATION COMPLEXES
#97Lipid nanoparticle compositions and methods for mRNA delivery
#98LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY
#99Lipid nanoparticle compositions and methods for MRNA delivery
#100Lipid nanoparticle compositions and methods for mRNA delivery
#101FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION
#102METHODS AND COMPOSITIONS FOR MODIFIED FACTOR IX PROTEINS
#103Stabilised Compositions of Factor VII Polypeptides
#104Lipid nanoparticle compositions and methods for mRNA delivery
#105Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#106Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
#107Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
#108AAV VIRIONS WITH DECREASED IMMUNOREACTIVITY AND USES THEREFOR
#109FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION
#110LONG-ACTING COAGULATION FACTORS AND METHODS OF PRODUCING SAME
#111MODIFIED FACTOR IX POLYPEPTIDES
#112Delivery and formulation of engineered nucleic acids
#113INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES
#114Optimized Liver-Specific Expression Systems for FVIII and FIX
#115Biodegradable lipids for delivery of nucleic acids
#116Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR)
#117ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR
#118CLOTTING FACTOR-FC CHIMERIC PROTEINS TO TREAT HEMOPHILIA
#119ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
#120Modified factor IX, and compositions, methods and uses for gene transfer to cells, organs, and tissues
#121RECOMBINANT AAV VECTORS USEFUL FOR REDUCING IMMUNITY AGAINST TRANSGENE PRODUCTS
#122Lipid nanoparticle compositions and methods for mRNA delivery
#123MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE
#124FX activation process and its use in the preparation of a FXa composition
#125METHOD OF DETECTING AND/OR IDENTIFYING ADENO-ASSOCIATED VIRUS (AAV) SEQUENCES AND ISOLATING NOVEL SEQUENCES IDENTIFIED THEREBY
#126LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE
#127Conjugates of biologically active molecules to functionalized polymers
#128COMBINATION OF FACTOR VII AND AN ANTI-FACTOR IX/X BISPECIFIC ANTIBODY
#129Methods for extracting proteins from a blood-based material
#130FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION
#131METHODS FOR TREATING DISORDERS ASSOCIATED WITH ANGIOGENESIS AND NEOVASCULARIZATION
#132MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF
#133FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION
#134CONCEPTS FOR THE TREATMENT OF GENETIC DISORDERS WITH HIGH-CAPACITY PLAL-GENERATED GOLD NANOPARTICLES
#135Modified factor VII polypeptides for subcutaneous administration and on-demand treatment
#136SINGLE CHAIN Fc FUSION PROTEINS
#137STABILIZED FACTOR IX FORMULATIONS CONTAINING TREHALOSE
#138Methods of treating neurological disorders
#139Medical Delivery Devices With Inhibited Oxygen Permeation
#140METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS
#141Short-acting heparin-based anticoagulant compounds and methods
#142VIRAL VECTORS ENCODING RECOMBINANT FIX WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA B
#143MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
#144Lipids and lipid nanoparticle formulations for delivery of nucleic acids
#145COMPOSITIONS COMPRISING HETEROGENEOUS POPULATIONS OF RECOMBINANT HUMAN CLOTTING FACTOR XA PROTEINS
#146Tissue factor pathway inhibitor antibodies and uses thereof
#147UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
#148IN VIVO PRODUCTION OF PROTEINS
#149Lyophilized factor IX formulations
#150MODIFIED FACTOR VII POLYPEPTIDES FOR SUBCUTANEOUS ADMINISTRATION AND ON-DEMAND TREATMENT
#151Method of targeting exosomes
#152Lipid nanoparticle compositions and methods for mRNA delivery
#153METHODS OF IMMUNOSTIMULATION WITH COMPLEXES OF RNA AND CATIONIC CARRIERS
#154Macrophage stimulating 1 receptor (MST1R) variants and uses thereof
#155POLYMER FACTOR IX MOIETY CONJUGATES
#156Factor IX polypeptides and methods of use thereof
#157Modified factor IX, and compositions, methods and uses for gene transfer to cells, organs, and tissues
#158FACTOR IX POLYPEPTIDES AND METHODS OF USE THEREOF
#159Short-acting Factor VII polypeptides
#160COMPOSITIONS AND METHODS FOR COUNTERACTING FACTOR XA INHIBITION
#161METHODS AND COMPOSITIONS FOR MODIFIED FACTOR IX PROTEINS
#162MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS
#163Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#164Lipid nanoparticle compositions and methods for mRNA delivery
#165SODIUM CHLORIDE SOLUTION FOR DRUG RECONSTITUTION OR DILUTION
#166Lyophilized formulations for factor Xa antidote
#167LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE
#168Compositions and methods for expressing factor IX
#169METHODS AND COMPOSITIONS RELATED TO LONG HALF-LIFE COAGULATION COMPLEXES
#170ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR
#171Therapeutic agents comprising a BMP-9 peptide and eleastin-like peptides
#172Antidotes for factor Xa inhibitors and methods of using the same
#173Factor IX polypeptide formulations
#174Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
#175Long-acting coagulation factors and methods of producing same
#176Stabilised Solid Compositions of Factor VII Polypeptides
#177MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
#178FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION
#179Biodegradable lipids for delivery of nucleic acids
#180Conjugates of biologically active molecules to functionalized polymers
#181Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
#182FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION
#183FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION
#184Tissue factor pathway inhibitor antibodies and uses thereof
#185Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
#186Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
#187FACTOR IX VARIANTS AND METHODS OF USE THEREFOR
#188SODIUM CHLORIDE SOLUTION FOR DRUG RECONSTITUTION OR DILUTION
#189Prohemostatic proteins for the treatment of bleeding
#190Prohemostatic proteins for the treatment of bleeding
#191Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
#192MODIFIED FACTOR IX, AND COMPOSITIONS, METHODS AND USES FOR GENE TRANSFER TO CELLS, ORGANS, AND TISSUES
#193MODULATION OF FACTOR Xa INHIBITOR-MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE
#194COAGULATION FACTOR IX WITH IMPROVED PHARMACOKINETICS
#195DELIVERY METHODS AND COMPOSITIONS FOR NUCLEASE-MEDIATED GENOME ENGINEERING
#196METHODS AND COMPOSITIONS FOR MODIFIED FACTOR IX PROTEINS
#197SUBCUTANEOUS ADMINISTRATION OF LONG-ACTING FACTOR IX IN HUMANS
#198Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
#199LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY
#200Methods and compositions related to a tissue factor-targeting IGG3 immunoconjugates
#201Methods of inducing immune tolerance to clotting factors
#202Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
#203Lipid formulations for delivery of messenger RNA
#204STABLE EXPRESSION OF AAV VECTORS IN JUVENILE SUBJECTS
#205Silicone free drug delivery devices
#206Stabilised Compositions of Factor VII Polypeptides
#207Liver-specific nucleic acid regulatory elements and methods and use thereof
#208METHODS OF USING A FIXED DOSE OF A CLOTTING FACTOR
#209Modified polynucleotides for the production of secreted proteins
#210Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#211Factor IX gene therapy
#212METHODS FOR TREATING DISORDERS ASSOCIATED WITH ANGIOGENESIS AND NEOVASCULARIZATION
#213Methods of treating hemophilic arthropathy using chimeric clotting factors
#214Cyclodextrins as procoagulants
#215POPULATION PHARMACOKINETICS TOOLS AND USES THEREOF
#216B-CELL ENGINEERING
#217Blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
#218Stabilised Solid Compositions of Factor VII Polypeptides
#219Lipid nanoparticle compositions and methods for mRNA delivery
#220Modified polynucleotides for the production of secreted proteins
#221In vivo production of proteins
#222AAV virions with decreased immunoreactivity and uses therefor
#223Blood coagulation protein conjugates
#224Procoagulant compounds
#225Antidotes for factor Xa inhibitors and methods of using the same
#226SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa
#227Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
#228POLYMERS FOR DELIVERY OF FACTOR VIII AND/OR FACTOR IX
#229Lipids and lipid nanoparticle formulations for delivery of nucleic acids
#230METHODS AND COMPOSITIONS FOR MODIFIED FACTOR IX PROTEINS
#231Engineered target specific nucleases
#232MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
#233Vectors for liver-directed gene therapy of hemophilia and methods and use thereof
#234COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE
#235Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders
#236Chimeric clotting factors
#237Extracellular histones as biomarkers for prognosis and molecular targets for therapy
#238Lipid nanoparticle compositions and methods for mRNA delivery
#239Factor IX polypeptides and methods of use thereof
#240Factor IX polypeptides and methods of use thereof
#241Lipid nanoparticle compositions and methods for mRNA delivery
#242METHODS OF TREATING A SUBJECT HAVING GLYCOGEN STORAGE DISEASE WITH mRNA ENCODING GLUCOSE-6-PHOSPHATASE CATALYTIC SUBUNIT (G6PC)
#243METHODS OF TREATING A SUBJECT HAVING PROPIONIC ACIDEMIA WITH mRNA ENCODING PROPIONYL-COA CARBOXYLASE, SUBUNIT ALPHA AND/OR BETA (PCCA AND/OR PCCB)
#244METHODS OF TREATING A SUBJECT HAVING CITRULLINEMIA WITH mRNA ENCODING ARGININOSUCCINATE SYNTHASE (ASS)
#245METHODS OF TREATING A SUBJECT HAVING FRIEDREICH'S ATAXIA WITH mRNA ENCODING FRATAXIN
#246METHODS OF TREATING A SUBJECT HAVING GLYCOGEN STORAGE DISEASE II WITH mRNA ENCODING ACID GLUCOSIDASE ALPHA (GAA)
#247METHODS OF TREATING A SUBJECT WITH mRNA ENCODING COAGULATION FACTOR VIII (F8)
#248METHODS OF TREATING PHENYLKETONURIA WITH MRNA ENCODING PHENYLALANINE HYDROXYLASE (PAH)
#249STABILIZED FACTOR IX FORMULATIONS CONTAINING TREHALOSE
#250MODIFIED BLOOD FACTORS COMPRISING A LOW DEGREE OF WATER SOLUBLE POLYMER
#251Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
#252Conjugates of biologically active molecules to functionalized polymers
#253Methods And Devices For Detection Of Anticoagulants In Plasma And Whole Blood
#254Stabilised Solid Compositions of Factor VII Polypeptides
#255ANTIBODY FORMULATIONS CONTAINING AMINO ACIDS
#256Single dose administration of factor VIIa
#257Methods of increasing nutrient absorption in the intestine using therapeutic agents comprising GLP-2 and elastin-like peptides
#258Systems and Methods for Nucleic Acid Expression In Vivo
#259Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets
#260Factor IX gene therapy
#261Delivery and formulation of engineered nucleic acids
#262Pharmaceutical formulations of PEGylated liposomes and blood coagulation factors
#263Methods for extracting proteins from a blood-based material
#264Liver-specific nucleic acid regulatory elements and methods and use thereof
#265Systems and methods for nucleic acid expression in vivo
#266LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE
#267Long-acting coagulation factors and methods of producing same
#268STABILIZING AGENT FOR PHARMACEUTICAL PROTEINS
#269Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
#270Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
#271SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa
#272Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#273Stabilised Compositions of Factor VII Polypeptides
#274METHODS, COMPOSITIONS AND KITS FOR REDUCING TISSUE ADHESIONS
#275Lipid formulations for delivery of messenger RNA
#276Blood factor monitoring assay and uses thereof
#277MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF COSMETIC PROTEINS AND PEPTIDES
#278Long-acting coagulation factors and methods of producing same
#279Compositions and methods for counteracting Factor Xa inhibition
#280Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia B
#281INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES
#282Translatable molecules and synthesis thereof
#283LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE
#284Modified Polynucleotides for the production of biologics and proteins associated with human disease
#285COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION
#286Single chain Fc fusion proteins
#287AAV VIRIONS WITH DECREASED IMMUNOREACTIVITY AND USES THEREFOR
#288Biodegradable lipids for delivery of nucleic acids
#289Biodegradable lipids for delivery of nucleic acids
#290Biodegradable lipids for delivery of nucleic acids
#291Biodegradable lipids for delivery of nucleic acids
#292Factor IX polypeptide mutant, its uses and method for its production
#293Compositions and Methods for Modulating Hemostasis
#294Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
#295Monoclonal antibodies against antithrombin beta
#296Combination Therapy with Coagulation Factors and Multispecific Antibodies
#297CLOTTING FACTOR-FC CHIMERIC PROTEINS TO TREAT HEMOPHILIA
#298Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same
#299Factor IX Polypeptides and Methods of Use Thereof
#300Factor IX polypeptides and methods of use thereof